Agreement between a regional pharmacovigilance centre and an adjudication committee regarding adverse drug reactions on a cohort of hospitalised children

Weda, 2017 Gallagher, 2011, Adverse drug reactions causing admission to a paediatric hospital: a pilot study, J Clin Pharm Ther, 36, 194, 10.1111/j.1365-2710.2010.01194.x WHO. World Health Organization, 2002 Dempsey, 2014, Who are the PDCO?, Eur J Pediatr, 173, 233, 10.1007/s00431-013-2096-2 Bourgeois, 2019, Promoting pediatric drug research and labeling — outcomes of legislation, N Engl J Med, 10.1056/NEJMhle1901265 Avant, 2018, Characteristics and changes of pediatric therapeutic trials under the best pharmaceuticals for children, Act J Pediatr, 192, 8 McMahon, 2018, Assessing drug safety in children — the role of real-world data, N Engl J Med, 378, 2155, 10.1056/NEJMp1802197 Moore, 2019, Pharmacovigilance - The next chapter, Therapie, 74, 557, 10.1016/j.therap.2019.09.004 Nguyen, 2021, Relationship between adverse drug reactions and unlicensed/off-label drug use in hospitalized children (EREMI): a study protocol, Therapies, 10.1016/j.therap.2021.01.057 Theophile, 2011 Agbabiaka, 2008, Methods for causality assessment of adverse drug reactions: a systematic review, Drug Saf, 31, 21, 10.2165/00002018-200831010-00003 Blanc, 1979, Judgments of trained observers on adverse drug reactions, Clin Pharmacol Ther, 25, 493, 10.1002/cpt1979255part1493 Karch, 1976, Adverse drug reactions-a matter of opinion, Clin Pharmacol Ther, 19, 489, 10.1002/cpt1976195part1489 Auriche, 1985, Bayesian approach to the imputability of undesirable phenomena to drugs, Therapie, 40, 301 Liang, 2014, Evaluation of the Reproducibility of the Naranjo Adverse Drug Reaction Probability Scale Score in Published Case Reports, Pharmacother J Hum Pharmacol Drug Ther, 34, 1159, 10.1002/phar.1496 Théophile, 2015, Validation and Reproducibility of the Updated French Causality Assessment Method: an Evaluation by Pharmacovigilance Centres & Pharmaceutical Companies, Therapie, 70, 465, 10.2515/therapie/2015028 Varallo, 2017, Imputation of adverse drug reactions: causality assessment in hospitals, PLoS ONE, 12 Carson, 2010, Determination of hospitalization type by investigator case report form or adjudication committee in a large heart failure clinical trial (β-Blocker Evaluation of Survival Trial [BEST]), Am Heart J, 160, 649, 10.1016/j.ahj.2010.07.004 Dechartres, 2009, Inadequate planning and reporting of adjudication committees in clinical trials: Recommendation proposal, J Clin Epidemiol, 62, 695, 10.1016/j.jclinepi.2008.09.011 Mahaffey, 2002, Misreporting of myocardial infarction end points: Results of adjudication by a central clinical events committee in the PARAGON-B trial, Am Heart J, 143, 242, 10.1067/mhj.2002.120145 Bégaud, 1985, Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France, Therapie, 40, 111 Naranjo, 1981, A method for estimating the probability of adverse drug reactions, Clin Pharmacol Ther, 30, 239, 10.1038/clpt.1981.154 Cohen, 1960, A coefficient of agreement for nominal scales, Educ Psychol Meas, 20, 37, 10.1177/001316446002000104 McHugh, 2012, Interrater reliability: the kappa statistic, Biochem Medica, 22, 276, 10.11613/BM.2012.031